The DOI matches its Crossref record; 80 of the 83 references it cites were found in a registry or an index.
Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
Open accessAbstract
Platinum complexes are clinically used as adjuvant therapy of cancers aiming to induce tumor cell death. Depending on cell type and concentration, cisplatin induces cytotoxicity, e.g., by interference with transcription and/or DNA replication mechanisms. Additionally, cisplatin damages tumors via induction of apoptosis, mediated by the activation of various signal transduction pathways, including calcium signaling, death receptor signaling, and the activation of mitochondrial pathways. Unfortunately, neither cytotoxicity nor apoptosis are exclusively induced in cancer cells, thus, cisplatin might also lead to diverse side-effects such as neuro- and/or renal-toxicity or bone marrow-suppression. Moreover, the binding of cisplatin to proteins and enzymes may modulate its biochemical mechanism of action. While a combination-chemotherapy with cisplatin is a cornerstone for the treatment of multiple cancers, the challenge is that cancer cells could become cisplatin-resistant. Numerous mechanisms of cisplatin resistance were described including changes in cellular uptake, drug efflux, increased detoxification, inhibition of apoptosis and increased DNA repair. To minimize cisplatin resistance, combinatorial therapies were developed and have proven more effective to defeat cancers. Thus, understanding of the biochemical mechanisms triggered by cisplatin in tumor cells may lead to the design of more efficient platinum derivates (or other drugs) and might provide new therapeutic strategies and reduce side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Platinum anticancer drugs, such as cisplatin, the most potent member of the platinum drug family, penetrate into the nucleus of cancer cells and form adducts with DNA leading to apoptosis [4].”
From Co-delivery of Paclitaxel and Cisplatin in Poly(2-oxazoline) Polymeric Micelles: Implications for Drug Loading, Release, Pharmacokinetics and Outcome of Ovarian and Breast Cancer Treatments (2019) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mohammad, R. M., Banerjee, S., Li, Y., Aboukameel, A., Küçük, Ö., & Sarkar, F. H. (2006) · Cancer · doi:10.1002/cncr.21731 · Cited by 77
RetractedMechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Lebwohl, D., & Canetta, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 754
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209009 · Cited by 552
The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
Hall, M. D., Okabe, M., Shen, D.-W., Liang, X.-J., & Gottesman, M. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.080907.180426 · Cited by 474
Cellular and molecular pharmacology of oxaliplatin.
Raymond, É., Faivre, S. J., Chaney, S. G., WOYNAROWSKI, J. M., & Cvitkovic, E. (2002) · PubMed · Cited by 463
Molecular mechanisms involved in cisplatin cytotoxicity
Jordan, P., & Carmo-Fonseca*, M. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000762 · Cited by 398
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts
Chaney, S. G., Campbell, S. L., Bassett, E., & Wu, Y. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.08.008 · Cited by 396
Particular aspects of platinum compounds used at present in cancer treatment
Desoize, B., & Madoulet, C. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00219-0 · Cited by 393
Modifications of DNA by platinum complexes
Brabec, V., & Kasparkova, J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.006 · Cited by 373
Research works printed but not linked: 3
- Trevisan, 2004, Erythrocyte aminolevulinic acid dehydratase inhibition by cisplatin, Toxicol. Lett., 152, 105
- Chattopadhyay, 2010, Metal complexes in medicine with a focus on enzyme inhibition, Curr. Opin. Chem. Biol., 14, 255, 10.1016/j.cbpa.2009.11.015 · DOI · Paper page
- Florea, A.-M., and Büsselberg, D. (2011). Cisplatin as an anti-tumour drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers, in press.
Cited by
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
Zhou, Z., Song, J., Nie, L., & Chen, X. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00271d · Cited by 2,098
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., Cheng, G., Lopez, M., & Kalyanaraman, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00042 · Cited by 1,683
Platinum-based drugs for cancer therapy and anti-tumor strategies
Zhang, C., Xu, C., Gao, X., & Yao, Q. (2022) · Theranostics · doi:10.7150/thno.69424 · Cited by 1,018
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z.-S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,017
Metadata
- Authors
- Florea, A.-M., & Büsselberg, D.
- Affiliations
- Heinrich Heine University Düsseldorf (DE)
- Weill Cornell Medical College in Qatar (QA)
- Corresponding author
- Büsselberg, Dietrich
- ORCID
- Büsselberg, Dietrich
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2011-03-15
- Volume
- 3
- Issue
- 1
- Pages
- 1351-1371
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC3756417
- OpenAlex
- W2073131323
- Cited by
- 1,759
- References
- 83
- Citations by year
- 2026: 65 · 2025: 111 · 2024: 154 · 2023: 148 · 2022: 165 · 2021: 177 · 2020: 195 · 2019: 176 · 2018: 133 · 2017: 129 · 2016: 100 · 2015: 82 · 2014: 70 · 2013: 28 · 2012: 21
- FWCI
- 19.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- cisplatin, platinum complexes, apoptosis, DNA replication inhibition, calcium signaling, death receptor signaling, mitochondrial apoptosis, drug resistance, neurotoxicity, nephrotoxicity, myelosuppression, combination chemotherapy, DNA repair, drug efflux, cellular uptake, platinum derivatives
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. https://app.cochat.ai/papers/10.3390/cancers3011351
- The paper
- Florea, A.-M., & Büsselberg, D. (2011). Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers. https://doi.org/10.3390/cancers3011351
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

